Article Information
Volume 18, Issue 2, pp. 448-458
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 17, 2018
- Revision received September 5, 2018
- Accepted November 26, 2018
- Published first February 4, 2019.
Article Versions
- Previous version (December 6, 2018 - 07:53).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Taylor J. Jensen1,*,
- Aaron M. Goodman2,3,
- Shumei Kato2,4,
- Christopher K. Ellison1,
- Gregory A. Daniels2,
- Lisa Kim2,
- Prachi Nakashe1,
- Erin McCarthy1,
- Amin R. Mazloom1,
- Graham McLennan1,
- Daniel S. Grosu1,
- Mathias Ehrich1, and
- Razelle Kurzrock2
- 1Sequenom, a Wholly Owned Subsidiary of Laboratory Corporation of America Holdings, San Diego, California.
- 2Division of Hematology/Oncology, Department of Medicine, Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, San Diego, California.
- 3Division of Blood and Marrow Transplantation, Department of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, California.
- 4Division of Precision Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, California.
- ↵*Corresponding Author:
Taylor J. Jensen, Sequenom, 3595 John Hopkins Court, San Diego, CA 92121. Phone: 858-202-9275; E-mail: tjensen{at}sequenom.com
T.J. Jensen and A.M. Goodman contributed equally to this article and are the co-first authors.
February 2019
Volume 18, Issue 2
Volume 18, Issue 2
Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients
Jump to section
Advertisement